Jonathan Pachter

Company: Verastem

Job title: Chief Scientific Officer

Seminars:

Exploring Optimal Combinations within Vertical & Parallel Pathways to Clinically Target NSCLC & Beyond 8:30 am

The validation and clinical progression of novel agents targeting critical nodes in vertical and parallel signaling pathways are crucial to address adaptive and acquired resistance. However, informing disease-specific combination regimens for NSCLC and other RAS pathway-driven malignancies is no easy feat, with challenges surrounding synergistic drug design, cancer histotypes, and diverse patient profiles. This workshop…Read more

day: Workshop B